Autologous dendritic cell therapy in canine splenic hemangiosarcoma

Hemangiosarcoma is an aggressive tumour that most frequently occurs in larger, middle-aged dogs of certain breeds. The spleen is the most commonly affected organ. This study aimed to evaluate the clinical effect of autologous, monocyte-derived dendritic cell (DC) therapy in canine hemangiosarcoma stage II after splenectomy. Dogs (n=452) diagnosed with splenic hemangiosarcoma that underwent splenectomy were enrolled. Of these, 42 dogs with stage II entered the DC therapy study. The median survival time for the total group of 42 dogs was 203 days. The median survival for the group (n=34) that received the full DC therapy (≥3 vaccines) was 256 ...

To read the full article you must log in with your EGO codes.

Use your EGO login data to access Vet.Journal

Username

Password Show Password

Remember Me

Sign in with a passkey

Log in

• Forgot your password?
• Forgot your username?

Check who can access Vet.Journal